PRODUCTS & SERVICES
CUSTOM OLIGO SYNTHESISRNA SEQUENCINGFLUORESCENT IN SITU HYBRIDIZATIONPERSONALIZED DIAGNOSTICS
Last week, MultiplexDX submitted a European patent application (EP 18198751.2) covering its Multiplex9+ diagnostic method. The innovation got the official title “Method for diagnosing diseases using multiplex fluorescence and sequencing” with the designated inventor listed as Dr. Pavol Cekan, Founder and CEO of MultiplexDX. The application protects both the 9th and 25th biomarkers’ diagnostic barcodes for breast cancer, which are used in Multiplex9+. It also protects the multiplexed combination of RNA visualization and sequencing, and all innovations used in MultiplexDX® RNA FISH and RNAseq technologies. Now the application is filed in two patent offices in Europe and Luxemburg, and MultiplexDX is going to convert it into a national patent application in the USA, Canada, Japan, and China.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
“This was an important step, actually an indispensable part of our business strategy, to secure the innovations. Nowadays, those companies who continue to promote and advance innovations should champion strong IP rights. MultiplexDX is among them! With a mission to become a policymaker in the market of biotech innovations, we are definitely on the right track!”
Currently, MultiplexDX is one of the most innovative biotechnology companies in Europe and the USA. Its goal is to introduce revolutionary technologies for oncology patients to the personalized, molecular diagnostic market. The innovative platform of MultiplexDX combines histopathological and molecular methods, as well as the precise quantification and visualization of RNA biomarkers into a single diagnostic test. This cross-validation approach eliminates misdiagnosis and creates a 100% accurate cancer profile for each patient. That will allow oncologists to design accurate, targeted and personalized treatment.
Reliable early-stage diagnostics is of the utmost importance and is the key to successful therapy. Thus, securing the patent for Multiplex9+ is so important. Introducing it to the market as soon as possible will save thousands of people from suffering and dying from cancer misdiagnosis all over the world.
The application was prepared and submitted in collaboration with the professional and award-winning German law firm Schiweck Weinzierl Koch (SWK).
Schiweck Weinzierl Koch advises and represents clients in all areas of European and international intellectual property rights, with an emphasis on life sciences. The company was established in January 2011 by its three partners, Dr. Wolfram Schiweck, Dr. Gerhard Weinzierl, and Dr. Andreas Koch. Since its establishment, this young and dynamic firm has expanded to include 20 lawyers in its modern working environment. As they specialize in the sciences, the company's patent attorneys have both strong technical expertise and an excellent understanding of the law. Even the most complex ideas are understood, protected, and defended down to the smallest detail.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.